News

Demand for the jab through the NHS and privately in pharmacies has remained steady since the end of the pandemic ...
EMA committee recommends marketing approval of Pfizer & BioNTech’s LP.8.1-adapted Covid-19 vaccine: New York Saturday, July 26, 2025, 10:00 Hrs [IST] Pfizer Inc. and BioNTech SE ...
As the country continues to deal with the fallout of the infamous Jeffery Epstein files, The Root is taking a closer look at ...
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the European Medicines Agency's (EMA) Committee for ...
An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...
A new study from Turkey has raised questions about the potential effects of the Pfizer-BioNTech COVID-19 vaccine on eye health, revealing changes in the cornea’s inner layer that may signal stress or ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages including the XFG and NB.1.8.1 variants1 compared to 2024-20 ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 202 ...
Patient safety means healthcare sets a particularly high standard for AI integration but the sector is increasingly ...
These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.
Here are five high-yield dividend stocks that offer passive income and solid entry points that investors can buy and forget ...